Japanese drugmaker Mochida Pharmaceutical announces that it has entered into an agreement with Qilu Pharmaceutical regarding ...

Oxford, UK-based Alethio Therapeutics, a biopharmaceutical company developing novel treatments for myeloproliferative ...

UK-based STORM Therapeutics, a biotech targeting RNA modifications to reprogram cells and develop novel cancer therapies, has ...

USA-based SQ Innovation has struck a long-term supply agreement with Italian active pharmaceutical ingredient (API) ...

US biotech Terremoto Biosciences, a firm developing highly-targeted small molecule medicines, has announced the closing of a ...

US health technology assessor the Institute for Clinical and Economic Review (ICER), in collaboration with Verdant Research, ...

US-based Sonire Therapeutics has secured $18 million in Series A financing to advance clinical development of its ...

German innovation hub BioMed X has launched its first research team in France, partnering with French pharma Servier to ...

German drugmaker Bayer (BAYN: DE) has highlighted publication of full results from its Phase III OCEANIC-STROKE trial in the ...

The US Food and Drug Administration will ask outside advisers in July whether some peptide substances should be allowed on ...

In what looks to be the largest follow-on stock offering in biopharma history, US oncology company Revolution Medicines ...

Privately-held Swiss drug firm Ewopharma has reported that sugemalimab, licensed from Chinese partner CStone Pharmaceuticals, ...